目的 探討清腦降壓膠囊聯(lián)合左氨氯地平治療原發(fā)性高血壓的臨床療效。方法 選取2021年6月—2024年6月深圳市龍華區(qū)人民醫(yī)院收治的116例原發(fā)性高血壓患者，按隨機數(shù)字表法分為對照組和治療組，每組各58例。對照組給予苯磺酸左氨氯地平片口服，2.5 mg/次，1次/d。治療組在此基礎(chǔ)上口服清腦降壓膠囊，3粒/次，3次/d。兩組療程均是8周。觀察兩組臨床療效，比較兩組治療前后診室血壓、相關(guān)量表[高血壓心身問卷、自測健康評定量表（SRHMS）、杜氏高血壓生活質(zhì)量量表]評分及血清C反應蛋白（CRP）、腫瘤壞死因子-α（TNF-α）、皮質(zhì)醇（Cor）、醛固酮（ALD）、血管緊張素Ⅱ（AngⅡ）水平。結(jié)果 治療組總有效率是98.28%，顯著高于對照組的86.21%（P＜0.05）。治療后，兩組診室DBP、SBP都低于組內(nèi)治療前（P＜0.05）；治療后，治療組診室DBP、SBP都低于對照組（P＜0.05）。治療后，兩組高血壓心身問卷評分都顯著降低，SRHMS和杜氏高血壓生活質(zhì)量量表評分顯著升高（P＜0.05）；治療后，治療組高血壓心身問卷評分低于對照組，而SRHMS和杜氏高血壓生活質(zhì)量量表評分高于對照組（P＜0.05）。治療后，兩組血清CRP、TNF-α、Cor、ALD和AngⅡ水平都低于同組治療前（P＜0.05）；治療后，治療組CRP、TNF-α、Cor、ALD和AngⅡ水平都低于對照組（P＜0.05）。結(jié)論 原發(fā)性高血壓采用清腦降壓膠囊聯(lián)合左氨氯地平治療，安全性較好，能有效調(diào)節(jié)患者機體炎癥狀態(tài)及內(nèi)分泌激素，促進血壓降低及心身癥狀、總體健康狀況和生活質(zhì)量的改善。

Objective To explore the clinical efficacy of Qingnao Jiangya Capsules combined with levoamlodipine in treatment of primary hypertension. Methods A total of 116 patients with primary hypertension admitted to People’s Hospital of Longhua, Shenzhen from June 2021 to June 2024 were selected and divided into control group and treatment group according to random number table method, with 58 patients in each group. Patients in control group were po administered with Levamlodipine Besilate Tablets, 2.5 mg/time, once daily. Patients in treatment group were po administered with Qingnao Jiangya Capsules on the basis of the control group, 3 grains/time, three times daily. Both groups were treated for 8 weeks. The clinical efficacy of the two groups was observed. The blood pressure of consultation rooms, the scores of relevant scales (Hypertension Psychosomatic questionnaire, SRHMS, Duchenne Hypertension Quality of Life Scale) scores and the levels of CRP, TNF-α, Cor, ALD, and AngⅡ were compared between two groups before and after treatment. Results The total effective rate of the treatment group was 98.28%, significantly higher than that of the control group (86.21%) (P < 0.05). After treatment, DBP and SBP in two groups were lower than before treatment (P < 0.05). After treatment, DBP and SBP in treatment group were lower than those in control group (P < 0.05). After treatment, psychosomatic questionnaire scores were significantly decreased in both groups, but SRHMS scores and Duchenne Hypertension Quality of Life scores were significantly increased (P < 0.05). After treatment, psychosomatic questionnaire scores in the treatment group were lower than those in control group, but SRHMS scores and Duchenne Hypertension Quality of Life scores were higher than those in control group (P < 0.05). After treatment, serum levels of CRP, TNF-α, Cor, ALD, and AngⅡ in two groups were lower than before treatment (P < 0.05). After treatment, the levels of CRP, TNF-α, Cor, ALD, and AngⅡ in treatment group were lower than those in control group (P < 0.05). Conclusion The treatment of primary hypertension with Qingnao Jiangya Capsules combined with levoamlodipine has good safety and can effectively regulate the inflammatory state and endocrine hormones of patients, promote blood pressure reduction, which can improve psychosomatic symptoms, overall health status, and quality of life.

R972

廣東省藥學會科學研究基金（2023KP09）